Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC203 TIL in Advanced Solid Tumors
NCT07256756Phase 1Recruiting
- Sponsor
- Juncell Therapeutics
- Start
- Jan 2026
- Primary completion
- Nov 2026
- Modality
- Gene Editing, Gene Silencing, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC203 in solid tumor, sponsored by Juncell Therapeutics. Primary endpoint: Adverse Events at 6 months. Started Jan 2026; status: recruiting.
02
Drugs
GC203
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07256756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07256756.